Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million

Reuters03-17

Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million

Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170700PRIMZONEFULLFEED9673148) on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620175426?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620175426","market":"nz","top_or_hot":-1,"title":"Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&amp;D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&amp;D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170700PRIMZONEFULLFEED9673148) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&amp;D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&amp;D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170700PRIMZONEFULLFEED9673148) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2djWYD:1","article_id":"2620175426","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620175426","pubTimestamp":1773745431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","GLUE":"Monte Rosa Therapeutics","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4539":"次新股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD"},"translate_title":"Monte Rosa第四季度净亏损扩大244%至4614万美元，收入下降95%至278万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":0.9,"NDAQ":0.9},"content_text":"Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million\n    \n\n        Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170700PRIMZONEFULLFEED9673148) on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620175426","isCrawlerRequest":true}